Food Supplements Purity Criteria (Magnesium L-threonate monohydrate) (England) Regulations 2026

Lord Blencathra Excerpts

Wednesday 10th June 2026 Grand Committee

I look forward in advance to any replies, and I completely understand if the Minister wishes to write to me on any of those issues, because we are broadly in support.

[Lord Blencathra (Con)]

My Lords, I thank the Minister for bringing forward this SI. These draft regulations are a purely technical measure, setting the purity criteria for magnesium L-threonate to be used in food supplements and for its legal sale and use, in compliance with the Food Supplements (England) Regulations 2003. This is a novel food. It was examined by the experts on the Advisory Committee on Novel Foods and Processes, which pronounced on its safety and uses. The current levels authorised in the novel foods authorisation are 250 milligrams of magnesium per day, which is roughly equivalent to 3,000 milligrams of magnesium L-threonate per day. This level was established based on health-based guidance values.

The Food Standards Agency consulted on this matter. I understand that concerns were raised during that consultation that the maximum level initially proposed for magnesium L-threonate in food supplements would result in a lower amount of base magnesium compared to the EU’s maximum level of 250 milligrams. This would have risked disadvantaging British businesses that market their products in the EU. The FSA, after consultation with outside organisations, agreed the level that we have before us, which is the same as the EU’s. On this occasion, UK scientists made that decision and it was not foisted upon us by the EU. The future, however, looks rather different.

The assessment of safety is not one set figure but a range, allowing this revision to a higher but still safe level. I commend the work of the independent experts in the ACNFP, whose assessment allowed this product to get approval. They get abuse from ignorant people, who complain that they do contract work for the food industry and therefore must be biased, but I do not want the Government to employ any so-called expert if he or she is not good enough to get contract work from an outside company. These are excellent people and I commend them.

I would like to raise some broader concerns about food regulation. There has been much noise about the Government’s intentions for dynamic alignment with the EU. The sanitary and phytosanitary—SPS—agreement involves 18 key agri-food policy areas. The Government want us to believe that this deal will simply ease traffic at our ports, when in fact it requires adopting thousands of EU laws, including future changes to them, over which we will have no say whatever. This includes policies such as those approving or restricting food texturisers, enhancers and processing aids; dictating vitamin dosages, mineral concentrations and ingredient reporting; and authorising emerging food technologies, synthetic alternatives and lab-grown products. Many noble Lords across this House will have views and insights on each of these areas, but they will be denied any say. More broadly, the deal risks sacrificing areas of growth and progress, such as precision breeding and gene-editing, or the development of vaccination programmes for cattle against MTBC, mycobacterium tuberculosis complex.

What assurances can the Minister give that these successes will continue under the SPS agreement? Will she clarify what safeguards, if any, are in place to ensure parliamentary oversight of future changes and to protect parliamentary sovereignty over UK law? These are important considerations; they are not relevant to the measure before us, but we will face them in future if the SPS agreement goes ahead. It is important that we have a say and can make recommendations over regulations such as those before us today. I look forward to hearing the Minister’s response and, as I said at the beginning, we welcome these regulations.

[Baroness Hayman of Ullock (Lab)]

My Lords, I thank noble Lords for their participation and questions in another short and sweet debate.

The noble Baroness, Lady Grender, asked about the EU and divergence, and the noble Lord just touched on that as well. To clarify, this form of magnesium has been approved as a novel food in the EU, where it can be used in food supplements. There are some minor differences between the EU’s and the Food Standard Agency’s assessments, but they do not create a material difference or any safety concerns. In the FSA’s view, the differences are due to differences in assessment style rather than in the product itself. In addition, the applicant has confirmed that the product, as manufactured, will comply with both the EU and GB specifications. That therefore does not give rise to any concerns regarding its trade between GB and the EU.

While we are on the EU, the noble Lord talked mainly about dynamic alignment and the legislation that will come with that, and asked for reassurances in that space. We are still in the middle of negotiations and I cannot go into the detail of them. They are not directly relevant to this statutory instrument, but the noble Lord knows that I am always more than happy to sit down, have a cup of tea and discuss these issues with him in detail as we move forward through the EU discussions. We know where we are on that.

Just to finish, the noble Baroness also talked about review periods, safety, and so on within that. Clearly, a lot of these areas are in the FSA’s area, and we in Defra—and, I know, the Department of Health and Social Care—meet regularly with our colleagues in the Food Standards Agency, because it is really important that we uphold standards and work very closely together. I will reference these concerns in our next meeting with the FSA, because the noble Baroness makes very important points that when we are bringing in new legislation around novel foods, we need to ensure that we are confident in their safety for the long term and that consumers are being suitably protected.

Having said all that, I remind noble Lords that this statutory instrument is very much a routine technical measure; it does not place any new burdens on businesses but ensures that use of the substance meets clear, consistent safety and quality standards. I thank noble Lords once again for their contributions and commend this SI to the Committee.